This Phase 2 trial evaluates BM219, a novel inhaled bispecific single-domain antibody designed to treat mild-to-moderate COVID-19. The study demonstrates that direct pulmonary delivery via nebulization is safe and effective, significantly accelerating clinical recovery and reducing viral loads even against highly immune-evasive variants like Omicron JN.1.
The Challenge of Evolving Variants and Systemic Delivery
As SARS-CoV-2 continues to evolve, many previously approved monoclonal antibodies (mAbs) have lost their potency. Subvariants like JN.1 have developed extensive mutations in the receptor-binding domain (RBD), allowing them to "escape" the immune system.
Furthermore, most clinical antibodies are administered systemically (via IV or injection). Because COVID-19 is primarily a respiratory disease, systemic delivery is inefficient; less than 0.2% of the injected antibody actually reaches the lungs. This necessitates massive, expensive doses and increases the risk of systemic side effects. This paper addresses the need for a variant-proof antibody that can be delivered directly to the site of infection.
Methods: Nebulized Bispecific Antibodies
Researchers developed BM219 (also known as bn03), a fully human, bispecific single-domain antibody (sdAb). Unlike traditional antibodies, sdAbs are much smaller and more thermally stable, making them ideal for aerosolization. BM219 targets two non-overlapping epitopes on the RBD, one of which is highly conserved across variants.
In this double-blind, randomized, placebo-controlled Phase 2 trial, 84 patients were randomized into four groups:
- Placebo
- 60 mg BID (twice daily)
- 120 mg QD (once daily)
- 120 mg BID (twice daily)
Treatments were administered via nebulizer for five consecutive days. The primary endpoints were safety and changes in viral load, while secondary endpoints included the time to sustained clinical recovery.
Key Results
Clinical Recovery
The study found that direct pulmonary delivery significantly shortened the duration of symptoms. The 60 mg BID group showed the most dramatic improvement, reaching sustained clinical recovery in a median of 172 hours, compared to 294.5 hours for the placebo group—a reduction of over five days.
Viral Load Reduction
In patients specifically infected with the JN.1 variant, the 120 mg BID group showed a -1.18 log10 copies/mL reduction in viral load compared to placebo by Day 5. While viral load reductions across the entire cohort were modest due to high levels of pre-existing immunity (vaccination or prior infection), the targeted delivery achieved high antibody concentrations in the sputum (~26,000 ng/mL in the high-dose group) while minimizing systemic exposure.
Safety and Tolerability
BM219 was well-tolerated. Interestingly, the incidence of adverse events (AEs) was lower in the treatment groups (45%) than in the placebo group (58.3%). No serious AEs were reported, confirming the safety of the nebulized sdAb approach.
Discussion and Limitations
The authors noted a "ceiling effect" of immunity; because participants had prior exposure to COVID-19, demonstrating massive drops in viral load is more challenging than in treatment-naive populations. Additionally, the 60 mg BID group showed faster clinical recovery than the 120 mg BID group, suggesting complex host-related immune responses or disease variability that require further study.
Conclusion
BM219 represents a potent new tool against variants that have rendered previous treatments obsolete. Its speed of symptom resolution is comparable to, or better than, existing oral antivirals like Paxlovid. A larger Phase 3 trial is currently in preparation to further validate these findings and assess long-term benefits in a broader population.
Summary updated